文献速递头颈部肿瘤放疗

同步顺铂联合剂量递增IMRT对比常规放疗治疗局部晚期头颈鳞癌:GORTEC 2004-01随机III期试验

Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
PubMed 文献 · Radiother Oncol · 2020-05-15

该随机III期试验纳入188例局部晚期头颈鳞癌患者,比较70Gy/35F 3D-RT与75Gy/35F IMRT同步顺铂的疗效。中位随访60.5个月,剂量递增IMRT未降低局部区域进展(调整HR=1.13,95%CI 0.64-1.98,P=0.68),生存无差异,但IMRT显著减少口干症。

要点

  • 剂量递增IMRT未改善局部区域控制,调整HR=1.13(95%CI 0.64-1.98,P=0.68)。
  • IMRT组口干症显著降低,1年≥2级口干症63% vs 23%(P<0.0001)。
  • 两组生存无差异,调整HR=1.19(95%CI 0.78-1.81,P=0.42)。

核心结论

  • 剂量递增IMRT同步顺铂未较标准3D-RT改善局部区域控制,但显著减少口干症。

研究设计与样本

  • 随机III期试验纳入188例局部晚期头颈鳞癌患者,随机分入70Gy/35F 3D-RT组(A组)或75Gy/35F IMRT组(B组)。
  • 两组均接受50Gy/25F后序贯推量,A组20Gy/10F,B组25Gy/10F至大体肿瘤体积,同步3周期顺铂100mg/m2。
  • 主要终点为局部区域进展(LRP),中位随访60.5个月。

主要发现

  • 剂量递增IMRT未降低LRP,调整HR=1.13(95%CI 0.64-1.98,P=0.68)。
  • 生存无差异,调整HR=1.19(95%CI 0.78-1.81,P=0.42)。
  • B组口干症显著减少,1年≥2级口干症(RTOG标准)63% vs 23%,3年45% vs 11%(P<0.0001)。
  • 未发现p16状态与治疗效应间的交互作用。

关键数值与推荐

  • A组:70Gy/35F/7周3D-RT,序贯推量20Gy/10F;B组:75Gy/35F IMRT,序贯推量25Gy/10F至GTV。
  • 两组同步顺铂100mg/m2,共3周期。
  • 1年≥2级口干症(RTOG标准)A组63%、B组23%;3年A组45%、B组11%。

临床怎么用

  • 对于局部晚期头颈鳞癌接受同步放化疗者,IMRT可显著降低口干症,支持其作为放疗技术选择。
  • 剂量递增至75Gy未显示局部区域控制获益,不建议仅以提高剂量为目的的递增。

局限性

  • p16状态仅记录于137例口咽肿瘤,其中53例(39%)为P16+。
  • 90%患者为吸烟者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concurrent chemoradiotherapy (CRT) is the standard of care (SoC) in locally advanced (LA) head and neck squamous cell carcinomas (HNSCC). This trial was designed to test whether dose-escalated IMRT and cisplatin could improve locoregional control without increasing complications over 3D-radiotherapy. METHODS: Patients were randomized between 70 Gy/35F in 7 weeks with 3D-RT (Arm A) versus 75 Gy/35F with IMRT (Arm B). Both arms received 50 Gy in 25 fractions followed by a sequential boost of 20 Gy/10F in Arm A and 25 Gy/10F to gross tumor volume in Arm B, as well as 3 cycles of cisplatin at 100 mg/m2 during RT. The primary endpoint was locoregional progression (LRP). RESULTS: 188 patients were randomized: 85% oropharynx and 73% stage IVa. P16 status was documented for 137 oropharyngeal tumors with P16+ in 53 (39%) patients; and 90% were smokers. Median follow-up was 60.5 months. Xerostomia was markedly decreased in arm B (p < 0.0001). The 1-year grade ≥2 xerostomia (RTOG criteria) was 63% vs 23% and 3-year 45% vs 11% in arms A and B, respectively. Xerostomia LENT-SOMA scale was also reduced in arm B. Dose-escalated IMRT did not reduce LRP with an adjusted HR of 1.13 [95%CI = 0.64-1.98] (p = 0.68). Survival was not different (adjusted HR: 1.19 [95%CI = 0.78-1.81], p = 0.42). No interaction between p16 and treatment effect was found. CONCLUSION: Dose-escalated IMRT did not improve LRC in LA-HNSCC patients treated with concomitant CRT over standard 3D-RT. This trial reinforces the evidence showing IMRT reduces xerostomia in LA-HNSCC treated with radiotherapy. Clinicaltrial.gov: NCT00158678.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Tao Y, Auperin A, Blanchard P, et al. Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial. Radiother Oncol. 2020. PMID: 32417348. doi:10.1016/j.radonc.2020.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。